drugset / Trial / NCT02472054
Treatment of Familiar Lymphohistiocytosis
Phase 1/2
Completed
29 enrolled
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this project is to study the number of surviving patients until hematopoietic stem cell transplantation (HSCT) after first line treatment of hemophagocytic lymphohistiocytosis (HLH) by Alemtuzumab
Timeline
- Start
- 2015-06-29
- Primary completion
- 2019-09-12
- Completion
- 2020-05-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Background | Cyclosporine | Peptide | — | Intravenous |
| Background | Methylprednisolone | Other / unclassified | 0.5 mg/kg | Intravenous |